Curcumin reduces COVID-19 risk: real-time meta analysis of 28 studies

Significantly lower risk is seen for mortality, ventilation, hospitalization, progression, recovery, and viral clearance. 19 studies from 17 independent teams in 9 countries show significant benefit.

Meta analysis using the most serious outcome reported shows 41% [30‑50%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies.

Results are very robust — in exclusion sensitivity analysis 27 of 28 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.

Control Curcumin

Studies typically use advanced formulations for greatly improved bioavailability.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Dietary sources may be preferred. The quality of non-prescription supplements varies widely1-3. All data and sources to reproduce this analysis are in the appendix.

6 other meta analyses show significant improvements with curcumin for mortality4-9, mechanical ventilation9, hospitalization4,7, recovery6,9, progression9, and symptoms4.

6 meta analyses show significant improvements with curcumin for mortality1-6, mechanical ventilation6, hospitalization1,4, recovery3,6, progression6, and symptoms1.